Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The RIPK1 inhibitor was removed from the list of active studies after it failed to meet its primary and secondary endpoints. The belief was that inhibiting the kinase may stop tissue damage and neuronal death by disrupting the production of cytokines and other…
Category: Multiple Sclerosis
Tolebrutinib in SPMS
31% delay in time to onset of confirmed disability progression in non-relapsing Secondary Progressive Multiple Sclerosis (SPMS) 20 September, 2024: Positive results from the HERCULES phase 3 study in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to…
FDA approves subcutaneous Ocrevus in the US
Ocrevus Zunovo is a twice yearly, under the skin treatment offered in clinic “This is something than can be provided in clinics and doesn’t require people to go to an infusion center,” David Jones, Genentech’s Medical Director for MS, said in an interview. “This will expand access to individuals who may not be able to…
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
First and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis 2 September 2024: Positive results from the HERCULES phase 3 study showed that tolebrutinib, Sanofi’s oral brain-penetrant BTK inhibitor, met the primary endpoint of improvement over placebo in delaying time to onset of confirmed disability progression (CDP) in people with…
How can scientists model the human brain?
bit.bio launches ioAstrocytes For the first time, scientists can now leverage the reproducibility of ioCells to study how the four major CNS cell types interact and contribute to neurological diseases. This enables more precise research and opens new doors for developing effective treatments. bit.bio, the company coding human cells for novel cures and a pioneer…
Evobrutinib in relapsing Multiple sclerosis
Results from the EVOLUTION clinical trials showed evobrutinib did not meet its primary endpoint of annualised relapse rate for up to 156 weeks compared to oral teriflunomide in both studies In two Phase III trials, evolutionRMS 1 and evolutionRMS 2, the compound known as evobrutinib failed to beat Sanofi’s established Aubagio in reducing MS relapse…
A prodrome for MS?
Study in Neurology evaluated the associations between diseases and symptoms diagnosed in primary care The researchers show that, on a population scale, the frequency of disorders such as depression, constipation, and urinary tract infections is associated with a diagnosis of multiple sclerosis five years later. These results outline a prodromal phase of the disease. Several studies have…
David Martin, CEO of the MS Trust to retire
David Martin has announced that following six years at the MS Trust, he plans to retire in early 2024. During his tenure at the MS Trust, David has overseen the establishment of both the Specialist Nurse and the Advanced MS Champion programmes. Working closely with the NHS, these schemes place Specialist MS Health Professionals in…
Switching to second line MS DMTs associated with decreased relapse rate
People with multiple sclerosis (MS) who switch between more than two disease-modifying therapies (DMTs) have a higher risk of relapses compared with those who never switch, regardless of how well these patients adhere to their prescribed medications, according to real-world study in Canada. According to the researchers, these findings are consistent with a greater number of treatment switches in…
